Further insights on the inhibition of HIV type 1 infection in vitro by CD4-modified synthetic peptides containing phenylalanine.

Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Further insights on the inhibition of HIV type 1 infection in vitro by CD4-modified synthetic peptides containing phenylalanine.

AIDS Res Hum Retroviruses. 1996 Jul 20;12(11):1023-30. Unique Identifier : AIDSLINE MED/96424757
Prieto I; Lasarte JJ; Sarobe P; Golvano J; Civeira MP; Gullon A; Prieto J; Borras-Cuesta F; Departamento de Medicina Interna, Facultad de Medicina,; Universidad de Navarra, Pamplona, Spain.

Abstract: Phenylalanine-containing peptides from CD4 were synthesized on the basis of chemical similarity with active CD4(81-92)-benzylated peptides. Systematic replacement of amino acids of these peptides bearing the benzyl group by phenylalanine, afforded several peptides that were able to block the binding of gp120 to CD4 and to inhibit HIV-induced syncytium formation. These experiments showed that substitution of residues 81 and 85 by phenylalanine was the most important for activity. Following optimization of the length of phenylalanine-substituted peptides it was found that FYICFVED and FYICFVEDE were the most active. Their IC50 for the inhibition of syncytium formation was around 1.2-1.6 microM. This activity is at least 30 times higher than that of the parent peptide FYIFFVEDQKEEDD previously reported (Lasarte et al., J Acquir Immune Defic Syndr 1994;7:129-134). Binding competition experiments with two different anti-peptide antisera recognizing the V3 region of gp120 and FYICFVEDE, show that the active peptides bind to V3 or to a sterically near region of V3. None of the active peptides was toxic to cells in vitro. The enhanced activity and simplicity of these new phenylalanine-substituted CD4 peptides might be a good starting point for the development of mimotopes of potential use for the treatment of AIDS.

Keywords: Acquired Immunodeficiency Syndrome/*PREVENTION & CONTROL Antigens, CD4/CHEMISTRY/*PHARMACOLOGY Antiviral Agents/CHEMISTRY/*PHARMACOLOGY Cell Fusion/DRUG EFFECTS Cell Line Enzyme-Linked Immunosorbent Assay Giant Cells/VIROLOGY Human HIV-1/*PATHOGENICITY In Vitro Oligopeptides/CHEMISTRY/*PHARMACOLOGY Peptide Fragments/CHEMISTRY/*PHARMACOLOGY *Phenylalanine Structure-Activity Relationship Support, Non-U.S. Gov't JOURNAL ARTICLE
970330
M9731495

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .